Related Researcher

Author's Photo

Ryu, Ja-Hyoung
Supramolecular NanoMaterials Lab (SUN)
Research Interests
  • Supramolecular assembly, synthetic peptide assembly, cancer drug delivery


Biodegradable Mesoporous Organosilica Nanoparticle Drug Delivery Platform with Dual-targeting Protein affibody

Cited 0 times inthomson ciCited 0 times inthomson ci
Biodegradable Mesoporous Organosilica Nanoparticle Drug Delivery Platform with Dual-targeting Protein affibody
Yang, GyeongseokOh, Jun YongRyu, Ja-Hyoung
Issue Date
Korean Chemical Society
125th General Meeting of the Korean Chemical Society
The usage of Protein Corona Silica Nanoparticles (PCSN) as a nanocarrier is effective targeting way of the drug delivery system. Because PCSN retain their abilities inside the body, dodging phagocytosis of the macrophage and protein serum inhibition. However, the investigation of controlled drug release profile of PCSN inside the cancer cell is still challenging for the perfection of the drug delivery. To give PCSN a function of the controlled release, the stimuli-responsive, and Biodegradable Mesoporous Organosilica Nanoparticles (MONs) could be better strategy in aspects of controlled release. MONs are consisted with silica containing disulfide bond, which responses with GSH of the tumor micro environment. The relatively higher level of GSH in the cancer cell can induce reaction with MONs. The disulfide bond of MONs can be reduced by the GSH and degraded achieving better release than the conventional Mesoporous Silica Nanoparticles (MSNs). This degradation can occur higher and faster amount of the delivery of the drug, leading to the effective cancer cell death. Not only enhancing the release profiles, to enhance the targeting ability of the PCSN nanocarrier, the protein modification had conducted with two kinds of the protein-affibody. Dual modification can induce the enhanced effect of the targeting cancer cells, giving universality to the nanocarrier, which is available of the target each different cells. Especially, it could target A431 cancer cell, which has both of the affibody receptor, showing more enhanced targeting ability than PCSN with a single affibody.
Appears in Collections:
CHM_Conference Papers
Files in This Item:
There are no files associated with this item.

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show full item record


  • mendeley


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.